AR073031A1 - Composiciones terapeuticas que contienen macitentan - Google Patents
Composiciones terapeuticas que contienen macitentanInfo
- Publication number
- AR073031A1 AR073031A1 ARP090103113A ARP090103113A AR073031A1 AR 073031 A1 AR073031 A1 AR 073031A1 AR P090103113 A ARP090103113 A AR P090103113A AR P090103113 A ARP090103113 A AR P090103113A AR 073031 A1 AR073031 A1 AR 073031A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically acceptable
- compound
- acceptable salts
- acceptable salt
- agonist
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 10
- 150000001875 compounds Chemical class 0.000 abstract 6
- 102000009079 Epoprostenol Receptors Human genes 0.000 abstract 3
- 108091006335 Prostaglandin I receptors Proteins 0.000 abstract 3
- 239000000556 agonist Substances 0.000 abstract 3
- 102000002045 Endothelin Human genes 0.000 abstract 2
- 108050009340 Endothelin Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 abstract 2
- OJQMKCBWYCWFPU-UHFFFAOYSA-N ACT-333679 Chemical compound C=1C=CC=CC=1C1=NC(N(CCCCOCC(O)=O)C(C)C)=CN=C1C1=CC=CC=C1 OJQMKCBWYCWFPU-UHFFFAOYSA-N 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 200000000007 Arterial disease Diseases 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229960002890 beraprost Drugs 0.000 abstract 1
- CTPOHARTNNSRSR-APJZLKAGSA-N beraprost Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC(O)=O CTPOHARTNNSRSR-APJZLKAGSA-N 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 229960001123 epoprostenol Drugs 0.000 abstract 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 abstract 1
- 229960002240 iloprost Drugs 0.000 abstract 1
- HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- JGCMEBMXRHSZKX-UHFFFAOYSA-N macitentan Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)NCCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 JGCMEBMXRHSZKX-UHFFFAOYSA-N 0.000 abstract 1
- 229960001039 macitentan Drugs 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- QXWZQTURMXZVHJ-UHFFFAOYSA-N selexipag Chemical compound C=1C=CC=CC=1C1=NC(N(CCCCOCC(=O)NS(C)(=O)=O)C(C)C)=CN=C1C1=CC=CC=C1 QXWZQTURMXZVHJ-UHFFFAOYSA-N 0.000 abstract 1
- 229960005032 treprostinil Drugs 0.000 abstract 1
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente se relaciona con un producto que contiene un compuesto de formula (1) o una sal farmacéuticamente aceptable de este compuesto, en combinacion con al menos un compuesto que tiene propiedades de agonista del receptor prostaciclina (IP), o una sal farmacéuticamente aceptable del mismo. Reivindicacion 2: Un producto de acuerdo con la reivindicacion 1, en el cual el compuesto que tiene propiedades de agonista del receptor de prostaciclina (IP) es seleccionado de entre treprostinil y sus sales farmacéuticamente aceptables, epoprostenol y sus sales farmacéuticamente aceptables, iloprost y sus sales farmacéuticamente aceptables, beraprost y sus sales farmacéuticamente aceptables, 2-{4-[(5,6-difenilpirazin-2- il)(isopropil)amino]butoxi}-N-(metilsulfonil)acetamida y sus sales farmacéuticamente aceptables, y ácido {4-[(5,6-difenilpirazin-2-il)(isopropil)amino]butoxi)acético y sus sales farmacéuticamente aceptables. Reivindicacion 5: Un producto que contiene macitentan o una sal farmacéuticamente aceptable de este compuesto, en combinacion con al menos un compuesto que tiene propiedades de agonista del receptor de prostaciclina (IP), o una sal farmacéuticamente aceptable del mismo, para uso terapéutico, de manera simultánea, separada o durante un periodo de tiempo, en el tratamiento de una enfermedad en la cual está involucrada la endotelina. Reivindicacion 9: Un producto de acuerdo con alguna de las reivindicaciones 5 a 8, en el cual la enfermedad en la cual está involucrada la endotelina es seleccionada de entre hipertension, hipertension pulmonar, arteriopatía diabética, falla cardíaca, disfuncion eréctil, angina pectoris y fibrosis pulmonar.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2008053252 | 2008-08-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073031A1 true AR073031A1 (es) | 2010-10-06 |
Family
ID=41346591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090103113A AR073031A1 (es) | 2008-08-13 | 2009-08-12 | Composiciones terapeuticas que contienen macitentan |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US8809334B2 (es) |
| EP (2) | EP2315587B1 (es) |
| JP (3) | JP5764061B2 (es) |
| KR (1) | KR101678699B1 (es) |
| CN (1) | CN102099026B (es) |
| AR (1) | AR073031A1 (es) |
| AU (1) | AU2009280843B2 (es) |
| BR (1) | BRPI0917661B8 (es) |
| CA (1) | CA2731370C (es) |
| CY (2) | CY1119826T1 (es) |
| DK (2) | DK3300729T3 (es) |
| ES (2) | ES2763176T3 (es) |
| HK (1) | HK1253355B (es) |
| HR (2) | HRP20171917T1 (es) |
| HU (2) | HUE036071T2 (es) |
| IL (1) | IL211143A0 (es) |
| LT (2) | LT2315587T (es) |
| MA (1) | MA32614B1 (es) |
| MX (1) | MX350011B (es) |
| MY (1) | MY178894A (es) |
| NO (1) | NO2315587T3 (es) |
| NZ (1) | NZ591601A (es) |
| PL (2) | PL3300729T3 (es) |
| PT (2) | PT2315587T (es) |
| RU (1) | RU2519161C2 (es) |
| SI (2) | SI2315587T1 (es) |
| SM (2) | SMT201700592T1 (es) |
| TW (1) | TWI446911B (es) |
| WO (1) | WO2010018549A2 (es) |
| ZA (1) | ZA201101900B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1928409E (pt) | 2005-09-12 | 2012-11-27 | Actelion Pharmaceuticals Ltd | Composição farmacêutica estável que compreende uma pirimidina-sulfamida |
| MX2010001837A (es) | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
| HRP20201352T1 (hr) * | 2008-02-28 | 2020-11-27 | Nippon Shinyaku Co., Ltd. | Inhibitor fibroze |
| LT2315587T (lt) | 2008-08-13 | 2018-01-10 | Actelion Pharmaceuticals Ltd. | Terapinės kompozicijos, turinčios macitentano |
| US9505737B2 (en) | 2013-01-11 | 2016-11-29 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| EP3712142B1 (en) | 2013-01-11 | 2022-07-06 | Corsair Pharma, Inc. | Prodrugs of treprostinil |
| US9643911B2 (en) | 2015-06-17 | 2017-05-09 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| US9394227B1 (en) | 2015-06-17 | 2016-07-19 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
| US9794795B1 (en) | 2016-04-29 | 2017-10-17 | Corning Optical Communications Wireless Ltd | Implementing a live distributed antenna system (DAS) configuration from a virtual DAS design using an original equipment manufacturer (OEM) specific software system in a DAS |
| EP4620525A3 (en) | 2016-12-14 | 2025-12-03 | Respira Therapeutics, Inc. | Methods and compositions for treatment of pulmonary hypertension and other lung disorders |
| MX2021001820A (es) * | 2018-09-14 | 2021-04-28 | Pharmosa Biopharm Inc | Composicion farmaceutica para la liberacion controlada de farmacos acidos debiles y usos de los mismos. |
| CA3123990A1 (en) * | 2018-12-21 | 2020-06-25 | Actelion Pharmaceuticals Ltd | Pharmaceutical composition for the treatment of pulmonary arterial hypertension |
| TW202042818A (zh) | 2019-01-25 | 2020-12-01 | 瑞士商艾克泰聯製藥有限公司 | 用於治療慢性血栓性肺高血壓之醫藥組成物 |
| CN114728002A (zh) | 2019-11-29 | 2022-07-08 | 埃科特莱茵药品有限公司 | 治疗肺动脉高血压的方法 |
| WO2021126884A1 (en) | 2019-12-16 | 2021-06-24 | Tenax Therapeutics, Inc. | LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-pEF) |
| EP4456897A4 (en) | 2021-12-31 | 2025-12-10 | Tenax Therapeutics Inc | ORAL FORMULATIONS OF LEVOSIMENDAN FOR THE TREATMENT OF PULMONARY HYPERTENSION WITH HEART FAILURE AND PRESERVED EJECTION FRACTION |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4539333A (en) * | 1976-05-11 | 1985-09-03 | Burroughs Wellcome Co. | Prostacyclin, methods of using and method of making |
| DE2845770A1 (de) * | 1978-10-19 | 1980-04-30 | Schering Ag | Neue prostacyclin-derivate und verfahren zu ihrer herstellung |
| JPS58124778A (ja) | 1982-01-20 | 1983-07-25 | Toray Ind Inc | ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体 |
| US4683330A (en) | 1984-03-08 | 1987-07-28 | The Upjohn Company | Interphenylene carbacyclin derivatives |
| HU229403B1 (en) * | 2000-12-18 | 2013-12-30 | Actelion Pharmaceuticals Ltd | Novel sulfamides and their use as endothelin receptor antagonists |
| EP1343506A1 (de) * | 2000-12-19 | 2003-09-17 | MERCK PATENT GmbH | Pharmazeutische formulierung enthaltend pyrazolo 4,3-d]pyrimidine und antithrombotica, calcium-antagonisten, prostaglandine oder prostaglandinderivate |
| DE10100426B4 (de) | 2001-01-08 | 2006-04-06 | Steag Hamatech Ag | Verfahren und Vorrichtung zum Zusammenfügen von Substraten |
| TWI316055B (es) * | 2001-04-26 | 2009-10-21 | Nippon Shinyaku Co Ltd | |
| WO2004017993A1 (en) * | 2002-08-12 | 2004-03-04 | Actelion Pharmaceuticals Ltd | Combination of prostacyclin or prostacyclin analogues and endothelin receptor antagonists for the treatment of pulmonary arterial hypertension |
| JP4769460B2 (ja) * | 2002-12-02 | 2011-09-07 | アクテリオン ファーマシューティカルズ リミテッド | 新規スルファミド類 |
| US20050101608A1 (en) | 2003-09-24 | 2005-05-12 | Santel Donald J. | Iloprost in combination therapies for the treatment of pulmonary arterial hypertension |
| TW200628467A (en) * | 2004-11-11 | 2006-08-16 | Actelion Pharmaceuticals Ltd | Novel sulfamides |
| PT1928409E (pt) * | 2005-09-12 | 2012-11-27 | Actelion Pharmaceuticals Ltd | Composição farmacêutica estável que compreende uma pirimidina-sulfamida |
| AR062501A1 (es) | 2006-08-29 | 2008-11-12 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas |
| US8541433B2 (en) | 2008-02-20 | 2013-09-24 | Actelion Pharmaceuticals, Ltd. | Combination comprising macitentan and paclitaxel for treating multi-drug resistant ovarian cancer |
| LT2315587T (lt) | 2008-08-13 | 2018-01-10 | Actelion Pharmaceuticals Ltd. | Terapinės kompozicijos, turinčios macitentano |
-
2009
- 2009-08-12 LT LTEP09786912.7T patent/LT2315587T/lt unknown
- 2009-08-12 TW TW098127151A patent/TWI446911B/zh active
- 2009-08-12 DK DK17191033.4T patent/DK3300729T3/da active
- 2009-08-12 HU HUE09786912A patent/HUE036071T2/hu unknown
- 2009-08-12 SM SM20170592T patent/SMT201700592T1/it unknown
- 2009-08-12 AR ARP090103113A patent/AR073031A1/es not_active Application Discontinuation
- 2009-08-12 PL PL17191033T patent/PL3300729T3/pl unknown
- 2009-08-12 MY MYPI2011000637A patent/MY178894A/en unknown
- 2009-08-12 NO NO09786912A patent/NO2315587T3/no unknown
- 2009-08-12 ES ES17191033T patent/ES2763176T3/es active Active
- 2009-08-12 EP EP09786912.7A patent/EP2315587B1/en not_active Revoked
- 2009-08-12 CA CA2731370A patent/CA2731370C/en active Active
- 2009-08-12 EP EP17191033.4A patent/EP3300729B1/en not_active Revoked
- 2009-08-12 SI SI200931770T patent/SI2315587T1/en unknown
- 2009-08-12 US US13/058,639 patent/US8809334B2/en active Active
- 2009-08-12 JP JP2011522608A patent/JP5764061B2/ja not_active Expired - Fee Related
- 2009-08-12 CN CN2009801279936A patent/CN102099026B/zh not_active Expired - Fee Related
- 2009-08-12 NZ NZ591601A patent/NZ591601A/xx unknown
- 2009-08-12 BR BRPI0917661A patent/BRPI0917661B8/pt not_active IP Right Cessation
- 2009-08-12 PT PT97869127T patent/PT2315587T/pt unknown
- 2009-08-12 ES ES09786912.7T patent/ES2652590T3/es active Active
- 2009-08-12 PT PT171910334T patent/PT3300729T/pt unknown
- 2009-08-12 LT LTEP17191033.4T patent/LT3300729T/lt unknown
- 2009-08-12 PL PL09786912T patent/PL2315587T3/pl unknown
- 2009-08-12 SI SI200932016T patent/SI3300729T1/sl unknown
- 2009-08-12 SM SM20190740T patent/SMT201900740T1/it unknown
- 2009-08-12 MX MX2011001625A patent/MX350011B/es active IP Right Grant
- 2009-08-12 HU HUE17191033A patent/HUE047767T2/hu unknown
- 2009-08-12 RU RU2011109084/15A patent/RU2519161C2/ru active
- 2009-08-12 HR HRP20171917TT patent/HRP20171917T1/hr unknown
- 2009-08-12 KR KR1020117003547A patent/KR101678699B1/ko active Active
- 2009-08-12 AU AU2009280843A patent/AU2009280843B2/en active Active
- 2009-08-12 DK DK09786912.7T patent/DK2315587T3/en active
- 2009-08-12 WO PCT/IB2009/053553 patent/WO2010018549A2/en not_active Ceased
-
2011
- 2011-02-10 IL IL211143A patent/IL211143A0/en active IP Right Grant
- 2011-03-07 MA MA33675A patent/MA32614B1/fr unknown
- 2011-03-11 ZA ZA2011/01900A patent/ZA201101900B/en unknown
-
2014
- 2014-07-18 US US14/335,657 patent/US9173881B2/en active Active
-
2015
- 2015-06-12 JP JP2015119021A patent/JP5956026B2/ja active Active
- 2015-06-12 JP JP2015119020A patent/JP5956025B2/ja active Active
- 2015-10-02 US US14/873,787 patent/US9597331B2/en active Active
-
2018
- 2018-01-19 CY CY20181100074T patent/CY1119826T1/el unknown
- 2018-10-03 HK HK18112650.6A patent/HK1253355B/en not_active IP Right Cessation
-
2019
- 2019-12-06 HR HRP20192204TT patent/HRP20192204T1/hr unknown
-
2020
- 2020-01-08 CY CY20201100016T patent/CY1122641T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR073031A1 (es) | Composiciones terapeuticas que contienen macitentan | |
| EA201100795A1 (ru) | Фармацевтическая композиция эффективного ингибитора всг для перорального введения | |
| CL2020002010A1 (es) | Uso de un polipéptido que comprende una hormona de crecimiento, y ctps adheridos a la misma, para inducir crecimiento o ganancia de peso. (divisional solicitud 201400254) | |
| ES2491140T3 (es) | Derivados de flavona enantioméricamente puros para el tratamiento de trastornos proliferativos y procesos para su preparación | |
| PE20140630A1 (es) | Derivados de acido 3-fenilpropionico ramificados y su uso | |
| ES2531009T3 (es) | Análogos sustituidos de dicetopiperazina para su uso como agentes para la administración de fármacos | |
| AR112532A2 (es) | Compuestos de tetraciclina sustituidos con flúor en c7 | |
| AR072261A1 (es) | Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos. | |
| AR111570A1 (es) | Composición farmacéutica que comprende selexipag | |
| AR055015A1 (es) | Derivados fusionados de pirazol composicion farmaceutica y uso del compuesto para fabricar medicamentos. | |
| LTPA2015023I1 (lt) | Ospemifeno bioaktyvumo padidinimo būdas | |
| JP2005531516A5 (es) | ||
| DOP2006000170A (es) | Nuevos derivados de espirocromanona | |
| ME02558B (me) | Inhibitori replikacije virusa gripa | |
| WO2006049835A3 (en) | Indole and benzimidazole derivatives | |
| MY151295A (en) | Pyrimidyl indoline compound | |
| EA201170676A1 (ru) | Агонисты рецептора меланокортина | |
| CL2013001558A1 (es) | El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico. | |
| AR075824A1 (es) | 2- mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3 | |
| PE20130236A1 (es) | Composicion farmaceutica que comprende un derivado de amida o una sal farmaceuticamente aceptable del mismo | |
| CY1114163T1 (el) | Μεθοδοι χρησεως ανταγωνιστων αγγειοπιεσινης με παραγοντες χημειοθεραπειας ανθρακυκλινης για να μειωνεται καρδιοτοξικοτητα ή/και να βελτιωνεται επιβιωση | |
| PE20110103A1 (es) | Derivado de piperidinilo como modulador de la actividad de los receptores de quimiocinas | |
| ES2545343T3 (es) | Utilización de la asociación de un inhibidor de la corriente If sinusal y un inhibidor de la enzima de conversión de la angiotensina para el tratamiento de la insuficiencia cardíaca con la función sistólica conservada | |
| PE20070806A1 (es) | Composicion farmaceutica que comprende un derivado de diarilurea | |
| CL2003002588A1 (es) | Uso de una composicion farmaceutica que comprende acido n,n-dimetoximetildifenil barbiturico, acido n-metoximetildifenil barbiturico o acido difenil barbiturico o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el t |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |